DANIEL HAMSTRA to Animals
This is a "connection" page, showing publications DANIEL HAMSTRA has written about Animals.
Connection Strength
0.189
-
MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner. Neoplasia. 2016 04; 18(4):213-22.
Score: 0.029
-
Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clin Cancer Res. 2009 Jan 15; 15(2):589-96.
Score: 0.018
-
Revoking the privilege: targeting HER2 in the central nervous system. Mol Pharmacol. 2008 Feb; 73(2):271-3.
Score: 0.016
-
Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol. 2007 Sep 10; 25(26):4104-9.
Score: 0.016
-
Real-time evaluation of p53 oscillatory behavior in vivo using bioluminescent imaging. Cancer Res. 2006 Aug 01; 66(15):7482-9.
Score: 0.015
-
Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor--a pharmacokinetic study. J Neurooncol. 2005 Jul; 73(3):225-38.
Score: 0.014
-
The use of 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies. Mol Ther. 2004 Nov; 10(5):916-28.
Score: 0.013
-
Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model. Radiat Res. 1999 Nov; 152(5):499-507.
Score: 0.009
-
Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther. 1999 Aug 10; 10(12):1993-2003.
Score: 0.009
-
Toward an enzyme/prodrug strategy for cancer gene therapy: endogenous activation of carboxypeptidase A mutants by the PACE/Furin family of propeptidases. Hum Gene Ther. 1999 Jan 20; 10(2):235-48.
Score: 0.009
-
Evaluation of D-methionine as a novel oral radiation protector for prevention of mucositis. Clin Cancer Res. 2008 Apr 01; 14(7):2161-70.
Score: 0.004
-
Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and TRAIL/Apo2L for cancer therapy. Clin Cancer Res. 2007 Mar 15; 13(6):1839-46.
Score: 0.004
-
Imaging of proteolytic activity using a conditional cell surface receptor. Mol Imaging. 2006 Apr-Jun; 5(2):129-37.
Score: 0.004
-
Inhibition of vascular endothelial growth factor (VEGF)-A causes a paradoxical increase in tumor blood flow and up-regulation of VEGF-D. Clin Cancer Res. 2006 Mar 01; 12(5):1525-32.
Score: 0.004
-
Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit. Gene Ther. 2006 Jan; 13(2):127-37.
Score: 0.004
-
Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker. Clin Cancer Res. 2004 Dec 01; 10(23):7852-9.
Score: 0.003
-
Extracellular expression of cytosine deaminase results in increased 5-FU production for enhanced enzyme/prodrug therapy. Anticancer Res. 2004 May-Jun; 24(3a):1393-9.
Score: 0.003
-
Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci U S A. 2002 Dec 24; 99(26):16551-5.
Score: 0.003
-
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. Gene Ther. 2000 Jun; 7(12):1005-10.
Score: 0.002
-
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A. 2000 Feb 15; 97(4):1754-9.
Score: 0.002
-
Carboxy-terminal conversion of profibrillin to fibrillin at a basic site by PACE/furin-like activity required for incorporation in the matrix. J Cell Sci. 1999 Apr; 112 ( Pt 7):1093-100.
Score: 0.002
-
Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest. 1998 Mar 01; 101(5):1102-10.
Score: 0.002
-
Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 1997 Dec 15; 57(24):5571-8.
Score: 0.002